ClinicalTrials.gg
Active, not recruitingNCT04948203Updated Dec 15, 2025

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

A Phase 2/3 interventional study of Sirolimus in Pulmonary Fibrosis, COVID-19 Pneumonia and Long COVID, sponsored by University of Chicago. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by University of Chicago · Phase 2/3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.

Planned enrollment
37th of 90
60 · median 50
Started
2021
with 10 others
Phase 2/3
2 of 128
none open now
Primary completion
2026-12
later than 12 of 38 live
Registered
91st of 128
by date

Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 37th largest by planned enrollment of the 90 interventional ones that give a count, is one of 11 that started in 2021, is one of 2 in phase 2/3, reaches primary completion later than 12 of the 38 other live ones, and was the 91st registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.

Read the detailed description

Hospitalized patients with a diagnosis of COVID-19 pneumonia will be referred to the study team for potential recruitment. Initial screening will take place using the existing medical record and in collaboration with the treating team. The study consists of 3 randomly assigned arms of varying dosages of the study drug

All procedures, with the exception of drug dosing and option sample analysis, align with the subject's standard of care. Prior to initiating study drug, the subject's standard of care labs, imaging and oxygen requirements will be reviewed.

Sirolimus will be administered as an oral medication. Subjects who are discharged prior to receiving 14 days of study drug will be provided with enough study drug to finish at home.

On-study evaluation includes measurement of vital signs and laboratory studies before and after a patient has received sirolimus while inpatient. As part of routine care, subjects will be seen daily while in the hospital and will be monitored through blood tests for general health as well as renal function. Vital signs will be monitored daily while in the hospital, physical exams, assessment of COVID-19, and CT scans or chest x-rays as necessary for routine care.

Subjects will return to clinic at 12 weeks for routine lab work and imaging as a part of study follow-up and will be assessed for pulmonary fibrosis at this time.

Additionally, University of Chicago Medicine patients will have the option to allow investigators to use leftovers from tubes of blood drawn for clinical tests that would otherwise be discarded. This will apply to any blood collected during that respective hospital stay as well as up to 1 year after study enrollment.

03

Conditions studied

  • Pulmonary Fibrosis
  • COVID-19 Pneumonia
  • Long COVID

Keywords

  • SECOVID
  • Sirolimus
  • Rapamune
  • Post-COVID Fibrosis
  • PASC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years of age
  • Approval from the patient's primary inpatient service
  • Hospitalized
  • Diagnosed with COVID-19 pneumonia
  • Positive test for active SARS-CoV-2 infection
  • Requiring supplemental oxygen ≥ 5LNC or ≥ 40% FiO2.
  • Chest computed tomography (CT) at admission with \< 10% pulmonary fibrosis
  • Ability to provide written on the part of the subject or, in the absence of decisional capacity of the subject, an appropriate surrogate (e.g. a legally authorized representative).

Exclusion criteria

Exclusion Criteria:

  • Known diagnosis of previous pulmonary fibrosis or an interstitial lung disease.
  • Clinical features or known diagnosis of or active non-COVID-19 infection, including untreated latent tuberculosis.
  • History of unstable or deteriorating cardiac disease (including myocardial infarction, coronary artery bypass surgery or angioplasty within the past 6 months, congestive heart failure requiring hospitalization within the past 6 months, or uncontrolled arrhythmia.
  • Known history of to sirolimus.
  • History of unstable or deteriorating neurologic disease (including TIAs or stroke).
  • Pregnant or lactating females. Females of child bearing potential are required to have a negative pregnancy test prior to treatment and practice abstinence or prevent pregnancy by at least a barrier method of .
  • therapy for any indication within 28 days prior to treatment.
  • Current treatment with any drugs that are strong inhibitors of .
  • Tofacitinib
  • Clarithromycin
  • Telithromycin
  • Nefazodone
  • Itraconazole
  • Ketoconazole
  • Atazanavir
  • Darunavir
  • Indinavir
  • Lopinavir
  • Nelfinavir
  • Ritonavir
  • Saquinavir
  • Tipranavir.
  • Inability or unwillingness to comply with the requirements for the trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Sirolimus 0.5mg

    Subject will take Sirolimus 0.5mg orally daily for 14 days.

    Drug: Sirolimus

  • Active comparator
    Sirolimus 1mg

    Subject will take Sirolimus 1mg orally daily for 14 days.

    Drug: Sirolimus

  • Active comparator
    Sirolimus 2mg

    Subject will take Sirolimus 2mg orally daily for 14 days.

    Drug: Sirolimus

Interventions

  • Triangular-shaped tablet

    Also known as: RAPAMUNE

06

What researchers measure

Primary outcomes

  1. Prevalence of Pulmonary Fibrosis as evidenced by CT scan

    Number of patients with \>10% pulmonary fibrosis on chest CT

    Time frame: 12 Weeks

Secondary outcomes

  1. 10% Threshold for Pulmonary Fibrosis evidenced by CT scan

    Number of patients with \>10% pulmonary fibrosis on chest CT

    Time frame: 12 Weeks

  2. Qualitative Fibrotic markers on chest CT

    Number of patients with the presence or absence of chest CT imaging markers of fibrosis

    Time frame: 12 Weeks

  3. Quantitative Fibrosis Score on chest CT

    Quantitative Fibrosis Score on chest CT

    Time frame: 12 Weeks

  4. Duration of Increased Supplemental Oxygen from Baseline

    Number of days over which the participant requires supplemental oxygen in excess over baseline supplemental oxygen requirement.

    Time frame: 84 Days

  5. Pulmonary Function Test impairment

    Number of subjects with the presence of abnormal indices of lung function tests

    Time frame: 12 Weeks

Other outcomes

  1. Safety - Rate of Liver Function Test abnormalities

    Number of patients in a study arm who develop severe impairment of liver function tests exceeding three times the upper limit of normal

    Time frame: 12 Weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2021
First posted
Jul 1, 2021
StartActual
Jul 9, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04948203
Responsible party
Sponsor
First posted
Jul 1, 2021
Start date
Jul 9, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 15, 2025

Study contacts

Ayodeji Adegunsoye, MD, MS
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion